Summary Growth of the EGF receptor-expressing non-small-cell lung carcinoma cell line H125 seems to be at least partially driven by autocrine activation of the resident EGF receptors. Thus, the possibility of an EGF receptor-directed antiproliferative treatment was investigated in vitro using a monoclonal antibody (cxEGFR ior egf/r3) against the human EGF receptor and gangliosides which are known to possess antiproliferative and anti-tyrosine kinase activity. The moderate growth-inhibitory effect of aEGFR ior egf/r3 was strongly potentiated by the addition of monosialoganglioside G M3 Likewise, the combination of aEGFR ior egf/r3 and GM3 inhibited EGF receptor autophosphorylation activity in Hi 25 cells more strongly than either agent alone. A synergistic inhibition of EGF receptor autophosphorylation by aEGFR ior egf/r3 and GM3 was also observed in the human epidermoid carcinoma cell line A431. In both cell lines, the inhibition of EGF receptor autophosphorylation by GM3 was prevented by pretreatment of the cells with pervanadate, a potent inhibitor of protein tyrosine phosphatases (PTPases). Also, GM3 accelerated EGF receptor dephosphorylation in isolated A431 cell membranes. These findings indicate that GM3 has the capacity to activate EGF receptor-directed PTPase activity and suggest a novel possible mechanism for the regulation of cellular PTPases.
Epidermal growth factor (EGF) is a 6-kDa peptide (Cohen and Carpenter, 1975 ) that binds to a 170-kDa transmembrane receptor (EGFR) with intrinsic tyrosine kinase activity (Ullrich and Schlessinger, 1990) . Ligand-induced receptor dimerization and autophosphorylation are essential subsequent steps for the initiation of intracellular events, which ultimately lead to EGF-induced cell division. The autophosphorylation of the EGFR is rapidly reverted by cellular PTPases, the identity of which remains to be established (Swarup et al, 1982; Charbonneau and Tonks, 1992; Faure et al, 1992; Pot and Dixon, 1992; Bohmer et al, 1993 . Apparently, different PTPases, including those of cytosolic or transmembrane type, have the capacity to dephosphorylate autophosphorylated EGFR (Hashimoto et al, 1992; Lammers et al, 1993) . Recently, the SH2-domain PTPase, PTP1C, has been shown to associate with the EGFR and to dephosphorylate it in A431 cells and in 293 cells overexpressing PTP1C and EGFR (Tomic et al, 1995) . Receptor dephosphorylation is considered a major mechanism of negative regulation of receptor activity.
A relation between the EGF/EGFR system and malignant cell transformation has been well established in experimental systems (Downward et al, 1984; Hayman et al, 1985; Derynck et al, 1987; Di Fiore et al, 1987; Velu et al, 1987) . More importantly, EGFR expression in human breast tumours has been correlated with a poor prognosis (Perez et al, 1984; Sainsbury et al, 1985; Received 17April 1996 Revised 7 August 1996 Accepted 8 August 1996 Correspondence to: R Perez and F-D Bohmer Macias et al, 1986 Macias et al, , 1987a Klijn et al, 1992) , and a link between EGFR activity and the malignant process has also been suggested for a number of other epithelial tumours, including non-small-cell lung cancer (NSCLC) (Khazaie et al, 1993; Modjtahedi and Dean, 1994; Fontanini et al, 1995) . Therefore, the evaluation of the EGF/EGFR system as a potential target for tumour therapy is highly warranted (Baselga and Mendelsohn, 1994a; Modjtahedi and Dean, 1994) . Different strategies have been employed to block EGFR signalling. Paradoxically, EGF itself can be inhibitory for cell growth under certain conditions (Barnes, 1982; Lombardero et al, 1986; Kamata et al, 1986) . Although the exact mechanism of this effect remains elusive, this principle was used successfully in a pilot clinical trial for treatment of skin epidermoid carcinoma (Fonseca et al, 1988) . Attempts to design on a peptide basis EGF antagonists that block EGF binding to its receptor have up to now had little success (Groenen et al, 1994) . Alternatively, anti-receptor antibodies have been generated in a number of laboratories and investigated with respect to a potential therapeutical application (Mueller et al, 1991; Fernandez et al, 1992; Fong et al, 1992; Modjtahedi et al, 1993; Reins et al, 1993 ; for a review see Baselga and Mendelsohn, 1994b) . Although some of the clinical data obtained so far are encouraging, the general impression emerges from these studies that antibody treatment alone will not be sufficient to combat EGFR-driven tumours, but will need combination with further antiproliferative agents (Baselga and Mendelsohn, 1994b) . A further strategy to block EGFR signalling would be the specific inhibition of receptor tyrosine kinase activity (Gibbs and Oliff, 1994; Levitzki and Gazit, 1995) . Recent efforts to obtain synthetic EGFR kinase inhibitors yielded quite potent and specific compounds, which might lead to useful pharmacological agents in the future. Among various naturally occurring tyrosine kinase inhibitors, the ganglioside, GM3, has been reported to attenuate EGFR signalling (Bremer et al, 1986; Hanai et al, 1988; Weis and Davis, 1990; Zhou et al, 1994) ; however, the mechanism of this effect is not well understood. Gangliosides are of low general toxicity and often have pronounced antiproliferative and differentiation-inducing properties (Hakomori, 1993; Svennerholm, 1994 ). In the current study, we therefore explored the possibility that a combined action of ganglioside GM3 and an anti-EGF receptor antibody, designated ocEGFR ior egf/r3 (Fernandez et al, 1992) , would lead to a more pronounced inhibition of the proliferation of EGFRexpressing tumour cell lines. We demonstrate a synergistic effect of xEGFR ior egf/r3 and GM3 on EGFR signalling activity and growth in H125 human NSCLC cells. Furthermore, our data suggest that activation of EGFR-directed PTPases by GM3 might, at least in part, constitute the mechanism underlying the inhibition of EGFR activity by GM .
MATERIALS AND METHODS Cells and reagents
Eleven different cell lines derived from human lung tumours were generously provided by Drs Gazdar (Dallas, TX, USA) and Bergh (Uppsala, Sweden). NCI H125 and NCI H23 originate from adenocarcinoma (Gazdar et al, 1980; Carney et al, 1985) ; U1810, NCI H 157 and NCI H661 originate from large-cell carcinoma (Bergh et al, 1982 (Bergh et al, , 1985 Carney et al, 1985) ; U1752 originates from a squamous cell carcinoma (Bergh et al, 1981) ; and NCI H82, U1285, U 1690, U 1906 and U2020 from small-cell carcinomas of the lung (Carney et al, 1985 , Bergh et al, 1982 . All lung cancer cell lines were grown in RPMI-1640 medium (Seromed, Berlin) supplemented with 10% fetal bovine serum (Gibco Life Technologies), 100 U ml penicillin and 100 U ml streptomycin and were kept at 37C in humidified atmosphere containing 5% carbon dioxide. A431 epidermoid carcinoma cells (CRL 1555) were obtained from the American Type Culture Collection (Rockville, USA). A43 1 cell culture and isolation of a membrane fraction were performed as described (Tomic et al, 1995) .
Human recombinant EGF was provided by the Center of Genetic Engineering and Biotechnology of Havana, Cuba. The monoclonal anti-EGF receptor antibody, ocEGFR ior egf/r3, was generated at the Center of Molecular Immunology of Havana as described earlier (Fernandez et al, 1992) . The antibody used in this study was purified from mouse ascites by protein A affinity chromatography. A CD3-specific monoclonal antibody of the same isotype (IgG 2A), designated 'ior t3' was also generated at the Center of Molecular Immunology of Havana. The monoclonal anti-EGF receptor antibody 425 (Rodeck et al, 1987) , designated 'aEGFR mab425', was kindly provided by Dr A Luckenbach (E Merck, Darmstadt, Germany). A monoclonal antibody against the C-terminus of human EGF receptor was obtained from Zymed (South San Francisco, USA) and is designated oaEGFR-CT. GM3 gangloside was purified from sheep spleen as described by Svennerholm (1973) . The purity of the preparation was determined by high-performance liquid chromatography (HPLC) and was at least 95%. The structure of the ganglioside was confirmed by FAB mass spectrometry. De-N-acetyl-GM3 was obtained from GM3 as described by Nores et al (1989) . The gangliosides were dissolved in phosphate-buffered saline (PBS) by sonication and then passed through a 0.2-gM sterile filter.
The specific EGFR-blocking tyrphostins, AG 1478 and AG 1517, were kindly provided by Drs Gazit and Levitzki (Jerusalem, Israel), (Fry et al, 1994; Osherov and Levitzki, 1994; Levitzki and Gazit, 1995) . They were dissolved in dimethyl sulphoxide (DMSO); for application in cell culture, the final DMSO concentration in the assays was < 0. 1%, only DMSO of the same concentration was included in the corresponding controls. Pervanadate was prepared from sodium orthovanadate stocks and hydrogen peroxide as described by Pumiglia et al (1992) .
EGF receptor assay
The amount of EGF receptor in the various lung cancer cell lines was measured as previously described (Macias et al, 1986) . Briefly, cells were seeded in 24-well plates (Costar) at 5 x 105 cells per well. On the next day, the culture medium was removed and the plates were washed three times with PBS containing 10 mm magnesium chloride and 10 mm calcium chloride. Then the cells were incubated with approximately 105 c.p.m. of ['25 ]EGF jCi jig-') in the absence or presence of different concentrations of unlabelled EGF in 0.5 ml of 10 mm Tris-HCl, pH 7.4, 10 mm magnesium chloride, 0.1% bovine serum albumin (BSA) (binding buffer) for 1 h at room temperature. Thereafter, the cells were washed with binding buffer and the bound radioactivity was recovered with 100 jil of 1M sodium hydroxide and measured in a gamma counter. Non-specific binding was estimated in the presence of 1000 ng ml-' EGF. Data were analysed according to Scatchard's method (Scatchard, 1949) .
Growth assay H125 cells were seeded in 24-well plates at 5 x 104 cells per well. One day later, the medium was replaced with RPMI medium containing 2% fetal bovine serum (FBS) and the desired effectors. This medium was changed every 2 days including renewal of effectors. At the desired time points, cell layers were washed with PBS and dissolved with 300 jil of 1.5 M sodium hydroxide for I h at room temperature, and the total amount of protein was determined. Alternatively, cells were labelled with [3H]thymidine (1 ,uCi ml', 2 jiM thymidine) for 18-24 h. Cell protein content and [3H]thymidine incorporation were linearly correlated under standard growth conditions of H 125 cells.
EGFR autophosphorylation and dephosphorylation assays Subconfluent cultures of H125 or A431 cells in six-well plates (Falcon) were treated overnight with serum-free medium. The medium was changed and the desired agents were added as described in the figure legends. Then the cells were stimulated with 1 jg ml-' EGF for 1 min at room temperature or left unstimulated. Cell extracts were prepared as described (Tomic et al, 1995) , using 200 jil of lysis buffer per well. About 20 jig or 5 jig of protein per lane of H125 or A431 cell extract, respectively, was analysed by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting with anti-phosphotyrosine antibodies (RC20-peroxidase conjugate, Transduction Laboratories) and ECL (Amersham) detection. Quantification was performed by densitometric scanning of the films and analysis using the program NIH image 1.52. To evaluate the amount of EGFR analysed, the blots were stripped and reprobed with the NSCLC cell growth inhibition by ganglioside GM3 215 Scatchard (1949) . bNSCLC, non-small cell lung carcinoma; SCLC, small-cell lung carcinoma; ADC, lung adenocarcinoma; LLC, lung large-cell carcinoma; SQC, squamos cell carcinoma. 
Growth modulation of H125 cells by EGF and EGFRspecific tyrosine kinase inhibitors
When H125 cells were treated with EGF at 10, 100 and 1000 ng ml-' in the presence of 1% fetal calf serum (FCS), the growth rate increased in a dose-dependent manner (Figure 1 ), albeit to a moderate extent. The relatively low potency of exogenously added EGF might be due to the constitutive presence of endogenous TGFa, which is known to be expressed in H125 cells (Soderdahl et al, 1988) . In order to test whether an autocrine pathway involving the EGFR contributes to the growth of these cells, the effect of a recently discovered highly specific EGFR tyrosine kinase inhibitor, designated AG 1478 (Osherov and Levitzki, 1994; Levitzki and Gazit, 1995) , was tested. H125 cells were cultured in the absence or presence of AG1478. AG 1478 treatment effectively inhibited stimulation of EGFR autophosphorylation by exogenously added EGF (Figure 2A ). Culturing H125 cells in the presence of AG1478 and in the absence of exogenously added EGF reduced the growth rate of the cells to about 69% in a concentration as low as 0.1 ,IM and to 3% at I ,UM ( Figure 2B ). In contrast, H661 NSCLC cells, which have undetectable EGFR levels (Table  1) , are resistant to treatment with AG1468, indicating that the effect of H125 is specific and non-toxic. Identical results were obtained with another EGFR tyrosine kinase inhibitor, AG1517 [PD 153035 (Fry et al, 1994) ] ( Figure 2B ). These findings suggest a partial dependence of H125 cell growth on EGFR signalling even in the absence of exogenously added EGF.
Growth modulation of H125 cells by anti-EGF receptor antibody aEGFR ior egf/r3 and ganglioside GM3
The previously described anti-EGF receptor antibody, aEGFR ior egf/r3 (Fernandez et al, 1992) , is known to inhibit EGF binding and EGFR signalling, and we wished to explore its potential usefulness for growth inhibition of EGFR-expressing NSCLC. As shown in Figure 3A , aEGFR ior egf/r3 inhibited the growth of H125 cells. Whereas 10 ,ug ml-' aEGFR ior egf/r3 used in this assay only had a small inhibitory effect, the cell growth rate was reduced to 50% and 41% at 30 and 100 jg ml-' respectively. The addition of an unrelated murine monoclonal antibody (axCD3 ior t-3) with identical isotype had no effect on proliferation of H125
British Journal of Cancer (1997) GM3 (20 gIM) plus ocEGFR ior egf/r3 almost completely inhibited cell growth and partially resulted in cell death. This cytotoxic effect was strictly mediated by EGFR, because the growth of the EGFR-negative cell line H661 was not significantly affected by the combination of ocEGFR ior egf/r3 and 5 g,M GM3 ( Figure 4B ). Also, the synergistic growth inhibition was specific for GM3, since De-N-acetylGM3 at 20 gM alone had only a slight effect on H 125 cell growth and did not further enhance the growth inhibition exerted by ocEGFR ior egf/r3 ( Figure 4A) . A very similar synergistic growth inhibition of H125 cells was also observed with the combination of another anti-EGFR antibody, otEGFR mab425, and GM3. Also, ocEGFR mab425 and GM3 synergistically inhibited growth of the EGFR-expressing NSCLC cell line, Ul 752 (data not shown).
Effect of the anti-EGF receptor antibody, ocEGFR ior egf/r3, and ganglioside GM3 on EGFR signalling activity
To evaluate whether the enhanced growth inhibition of HI 25 cells exerted by ocEGFR ior egf/r3 in the presence of the ganglioside GM3 is mediated by an enhanced inhibition of EGFR signalling activity, the effect of both agents on EGFR autophosphorylation was investigated. Intact H125 cells were pretreated with ocEGFR ior egf/r3, GM3 or both. Thereafter, the cells were stimulated with EGF, lysed and the extent of EGFR autophosphorylation was measured by immunoblotting with anti-phosphotyrosine antibodies. EGFR autophosphorylation was inhibited by axEGFR ior egf/r3 in a dose-dependent manner ( Figure 3B ). Treatment of the cells with 50 ,ug mll aEGFR ior egf/r3 resulted in a reduction of EGFR autophosphorylation to 43% ( Figure 4C, Figure 4C, lower panel) . Thus, the combined action of xEGFR ior egf/r3 and GM3 leads to an inhibition of EGFR autophosphorylation, which is qualitatively matching the observed synergistic inhibition of H125 cell growth. For comparison, the effects of GM3 and aEGFR ior egf/r3 on EGFR autophosphorylation in A43 1 human epidermoid carcinoma cells were investigated. As shown in Figure 5A . , , , , , , , . . , . . . . . . . . . . . , g , . . . . Interestingly, when the A43 1 cell treatment was performed in the presence of pervanadate, a potent inhibitor of PTPases (Pumiglia et al, 1992) , the inhibition of EGFR autophosphorylation by GM3 as well as the synergistic inhibition of EGFR autophosphorylation by GM3 and xEGFR ior egf/r3, was abolished ( Figure SC) . Also, GM3-mediated inhibition of EGFR autophosphorylation in H 125 cells is prevented by pervanadate treatment ( Figure 4D NSCLC cell growth inhibition by ganglioside GM3 219 investigated the effect of a combined antiproliferative cell treatment with the anti-EGF receptor antibody, cEGFRior egf/r3, and gangliosides, again using the NSCLC line H125 as a target. Indeed, ganglioside GM3 (but not De-N-acetlylGM3) was found greatly to potentiate the effect of axEGFR ior egf/r3 on the growth of these EGFR-expressing cells leading to almost complete growth arrest and cytotoxicity. This effect was dependent on the presence of EGFR, since growth of an NSCLC line lacking EGFR expression was completely unaffected by the combined treatment. Synergistic growth inhibition was also observed using another NSCLC cell line (U 1752) as target or using the combination of another anti-EGFR antibody (ocEGFR mab425) and GM3 for the treatment, suggesting that the observed synergism is general. Experiments are underway to analyse further this new cytostatic concept in experimental tumours in vivo. A similar synergistic growth inhibition by a combination of an anti-EGFR antibody and a synthetic tyrosine kinase inhibitor has been observed for a squamous cell carcinoma by Yoneda et al (1991) .
When we compared the effect of various treatments of H125 cells on cell growth with that on EGFR autophosphorylation activity, we observed an overall correlation of the inhibitory effects. Cell growth was blocked by specific EGFR tyrosine kinase inhibitors, the anti-EGF receptor antibody ocEGFR ior egf/r3 inhibited receptor autophosphorylation and the combination of axEGFR ior egj/r3 and GM3 had a stronger effect on EGFR autophosphorylation than either agent alone. Taken together, these correlations suggest that the observed EGFR tyrosine kinase inhibition is causally related to growth inhibition. Some differences in the dose -response characteristics for growth inhibition and kinase attenuation were, however, observed. Most notably, the combined inhibition by ocEGFR ior egf/r3 and GM3 was less pronounced on the level of H125 cell EGFR autophosphorylation than on the level of cell growth. These quantitative differences might be a result of the somewhat different treatment and assay schedules for the two parameters. It is, however, currently not possible to exclude additional effects of the agents used on other cellular systems contributing to the observed growth inhibition.
Growth factor receptor signalling activity at the level of receptor autophosphorylation is the net result of the action of receptor PTK and opposing PTPases. We therefore investigated whether the synergistic inhibitory effect of xEGFR ior egf/r3 and GM3 on the EGFR autophosphorylation involved merely tyrosine kinase inhibition or possibly also effects on the EGFR-directed PTPase(s). Interestingly, the attenuation of EGFR autophosphorylation by GM3 in H125 cells and in A431 cells is abrogated by pretreatment of the cells with the PTPase inhibitor, pervanadate. Furthermore, GM3 has the capacity to activate EGFR dephosphorylation in A43 1 cell membranes in vitro. Thus, activation of EGFR-directed PTPases by GM3 seems to be involved in the attenuation of EGFR signalling activity, possibly in addition to a direct tyrosine kinase inhibition (Zhou et al, 1994) . It seems tempting to speculate that PTPase activation is also likely to be involved in the enhancement of anti-EGFR antibody-mediated growth inhibition by GM3 in H125 NSCLC cells. The identity of the activated PTPase(s) is currently unknown. The SH2-domain PTPase IC has been shown to attenuate EGFR signalling in A43 1 cells; however, it is unlikely that this cytosolic PTPase is affected by exogenously added GM3. Rather transmembrane PTPases (Charbonneau and Tonks, 1992; Pot and Dixon, 1992) are candidate targets for GM3 action. One could envisage GM3 effects on such PTPases either via the membrane spanning or via the extracellular protein domains. The observed activation by GM3 might help to identify further PTPases involved in EGFR dephosphorylation and might present a new regulatory principle for PTPases. Furthermore, our findings lend support to the concept that activation of growth factor receptordirected PTPases could be employed as a mechanism for novel antiproliferative agents. ABBREVIATIONS EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; EDTA, ethylenediamine tetraacetic acid; FCS, fetal calf serum; DMSO, dimethyl sulphoxide; SCLC, small-cell lung carcinoma; NSCLC, non-small-cell lung carcinoma; SDS, sodium dodecyl sulphate; PAGE, polyacrylamide gel electrophoresis; PTPase, protein tyrosine phosphatase.
